Oncology Corporate Profile
| 2.2050 | |
| 0.0250 |
CASI is a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China.
Website: http://www.casipharmaceuticals.com
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| ENMD-2076 | aurora A/angiogenic kinase inhibitor | Fibrolamellar Carcinoma | II | |
| ENMD-2076 | aurora A/angiogenic kinase inhibitor | Ovarian cancer | II | |
| ENMD-2076 | aurora A/angiogenic kinase inhibitor | Sarcoma | II | |
| ENMD-2076 | aurora A/angiogenic kinase inhibitor | Triple negative Breast cancer | II |
View additional information on product candidates here »
3/31/2017 01:00 pm
3/31/2017 11:00 am
[PR Newswire] - ROCKVILLE, Md., March 31, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...
3/28/2017 11:00 am
[PR Newswire] - ROCKVILLE, Md., March 28, 2017 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, ...
12/16/2016 09:03 pm
12/5/2016 04:03 pm
12/5/2016 04:03 pm
12/5/2016 12:02 pm
12/5/2016 12:00 pm
[PR Newswire] - ROCKVILLE, Md., Dec. 5, 2016 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announced today that China's Food and Drug Administration (CFDA) has accepted for review the Company's import drug registration application for EVOMELA® (melphalan) for Injection. CASI's China rights to EVOMELA (melphalan) for Injection was previously licensed from its partner Spectrum Pharmaceuticals, Inc. along with two other commercial-stage Spectrum drugs, MARQIBO® and ZEVALIN®. EVOMELA received U.S. FDA approval earlier this year for multiple myeloma patients as a high-dose conditioning treatment prior to autologous stem cell transplantation (ASCT) and as palliative treatment for patients who are not candidates for oral therapy. It was launched in the U.S. this year by Spectrum.
11/19/2016 06:00 pm
Follow @OBRTweets